(Q36598311)

15 August 2017

1 reference

title

Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway (English)

1 reference

15 August 2017

Wolf G

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

20 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

70

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1914-1919

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001846

15 August 2017

exact match

0 references

cites work

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Cytokines in kidney disease: the role of transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Epithelial-mesenchymal transition and its implications for fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor-beta regulation of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

TGF-beta impairs renal autoregulation via generation of ROS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Emilin1 links TGF-beta maturation to blood pressure homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Link between angiotensin II and TGF-beta in the kidney.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II and renal fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II and progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

BMP-7 and the proximal tubule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Stimulation of autocrine platelet--derived growth factor AA-homodimer and transforming growth factor beta in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Smad transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Essential role of Smad3 in angiotensin II-induced vascular fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II increases connective tissue growth factor in the kidney.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Induction of connective tissue growth factor by angiotensin II: integration of signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Effect of aldosterone on renal transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Renin/prorenin receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Receptor-mediated actions of renin and prorenin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Induction of p27KIP1 after unilateral ureteral obstruction is independent of angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Urinary transforming growth factor-beta 1 in membranous glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Accurate measurement and clinical significance of urinary transforming growth factor-beta1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001846

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001846

1 reference

Dimensions Publication ID

15 August 2017

1012378966

0 references

1 reference